Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
Phase 3
Recruiting
- Conditions
- Radiotherapy; ComplicationsEffect of Radiation TherapyBreast Cancer
- Interventions
- Radiation: Medial supraclavicular lymph node radiotherapyRadiation: Entire supraclavicular lymph node radiotherapy
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1650
- Registration Number
- NCT05059379
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05057845
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
Phase 2
Recruiting
- Conditions
- Liver MetastasesColorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05057052
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
Recruiting
- Conditions
- Radiation DermatitisReconstructive SurgerySkin MicrobiomeBreast Cancer
- Interventions
- Radiation: post-operative radiotherapy
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT05032768
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
Phase 2
Withdrawn
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- Drug: GP+PD-1+Tight
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Fudan University
- Registration Number
- NCT05019677
- Locations
- 🇨🇳
Zhongshan hospital, Fudan University, Shanghai, Shanghai, China
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 32
- Registration Number
- NCT05018702
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
ARX788 in Breast Cancer With Low Expression of HER2
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 54
- Registration Number
- NCT05018676
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Health Benefits of Air Purifiers in Primary School Students
Not Applicable
Active, not recruiting
- Conditions
- Cardiopulmonary FunctionChild
- Interventions
- Behavioral: Air purifier and fresh air ventilation systems with high-efficiency particulate air (HEPA) filtersBehavioral: Air purifier and fresh air ventilation systems without high-efficiency particulate air (HEPA) filters
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 110
- Registration Number
- NCT05016271
- Locations
- 🇨🇳
Department of Environmental Health, School of Public Health, Fudan University, Shanghai, Shanghai, China
Cryoablation Combined with Sintilimab Plus Lenvatinib in Patients with Advanced Intrahepatic Cholangiocarcinoma
Phase 2
Completed
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 28
- Registration Number
- NCT05010668
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Phase 2
Recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05010681
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath